Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | NEU3 | Q9UQ49 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | FGF1 | P05230 | 2/20 | 0.33 |
| ▸ | FGF2 | P09038 | 2/20 | 0.33 |
| ▸ | VEGFA | P15692 | 2/20 | 0.33 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14075625 | 1.00 | NT5E (0.36) | NT5ENEU3CYP2D6ALDH1A1MAPK1 | |
| SCHEMBL472853 | 0.85 | NT5E (0.44) | NT5EPOLBFGF1FGF2VEGFA | |
| SCHEMBL14075626 | 0.84 | LGALS8 (0.42) | NT5ECYP2D6ALDH1A1MAPK1POLB | |
| SCHEMBL472852 | 0.84 | LGALS8 (0.42) | NT5ECYP2D6ALDH1A1MAPK1POLB | |
| SCHEMBL2629582 | 0.84 | LGALS8 (0.42) | NT5ECYP2D6ALDH1A1MAPK1POLB | |
| SCHEMBL472876 | 0.80 | FGF1 (0.37) | NT5ECYP2D6ALDH1A1MAPK1POLB | |
| SCHEMBL14409790 | 0.78 | NT5E (0.51) | NT5EFGF1FGF2VEGFAHPSE | |
| SCHEMBL14409788 | 0.77 | LGALS8 (0.48) | NT5ECYP2D6ALDH1A1MAPK1POLB | |
| SCHEMBL14075622 | 0.77 | LGALS8 (0.48) | NT5ECYP2D6ALDH1A1MAPK1POLB | |
| SCHEMBL2629592 | 0.77 | LGALS8 (0.48) | NT5ECYP2D6ALDH1A1MAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158763-B2 | Lipophilic protected, asparagine-linked oligosaccharide derivative containing a fucose in N-acetylglucosamine on nonreducing terminal side | Kajihara, Yasuhiro (JP) | 2012-04-17 | — | — | US | disclosed |
| US-8063202-B2 | Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides | OTSUKA CHEMICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-7943763-B2 | Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides | OTSUKA CHEMICAL HOLDINGS CO., LTD. (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20090234095-A1 | Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides | GLYTECH, INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| US-7304148-B2 | Sugar chain asparagine derivatives, sugar chain asparagine, sugar chain, and processes for producing these | OTSUKA CHEMICAL CO., LTD. (JP) | 2007-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234095-A1 | Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides | ASNS, ANPEP, B3GNT2 | NT5E 325/4885NEU3 16/4885CYP2D6 4648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.